Hormone Health Data and Research Act
HB9077, titled the Hormone Health Data and Research Act, directs federal health agencies to review existing scientific evidence on hormone variability and hormone testing in women as it relates to perimenopause. The bill requires the National Institutes of Health to evaluate published evidence on how hormone levels may vary before perimenopausal symptoms begin and whether there is a baseline pattern in that variability.
The bill also directs the Secretary of Health and Human Services, through the U.S. Preventive Services Task Force, to review evidence on the clinical usefulness of hormone testing, including whether baseline hormone information collected before symptoms appear can help diagnose or manage perimenopause. Within 18 months of enactment, NIH and USPSTF must report their findings, identify evidence gaps, and make recommendations for future research or clinical guidance to congressional committees.
The bill does not directly change coverage rules, clinical standards, or patient rights, but it would require NIH and the USPSTF to conduct formal evidence reviews and submit a report to Congress. Its practical effect would be to elevate perimenopause and hormone testing as a federal research and public health priority, potentially shaping future clinical guidance, research funding, and preventive care recommendations. It would affect federal health agencies, researchers, clinicians, and women seeking evaluation for perimenopause-related symptoms.
Based on the bill text and available context, the measure appears broadly supportive of women’s health research and data collection, with an emphasis on filling evidence gaps rather than mandating treatment or coverage changes. Because there are no recorded committee transcripts or votes in the provided material, there is no documented opposition or support beyond the bill’s stated purpose. The tone of the legislation is exploratory and evidence-driven, suggesting a generally neutral-to-positive reception at introduction.
The main potential point of contention is whether hormone testing before or during perimenopause has sufficient clinical utility to justify federal attention, since the bill specifically asks agencies to assess whether baseline hormone measurements meaningfully improve diagnosis or management. Another possible issue is the scope of federal involvement in an area where evidence may still be limited, with some stakeholders likely favoring more research before any clinical guidance is developed. No specific opposing members, advocacy groups, or amendments are identified in the provided record.